Quick Answer
Ovid Therapeutics Inc. reported Operating Income Loss of -$42.44 million for the year ending 2025.
- Ovid Therapeutics Inc. showed an increase of +31.4% in Operating Income Loss from 2024 to 2025.
- This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$5.42 million | Q3 2016: -$5.81 million | Q1 2017: -$34.26 million | Q2 2017: -$10.29 million | Q3 2017: -$9.41 million | Q1 2018: -$13.43 million | Q2 2018: -$13.21 million | Q3 2018: -$13.18 million | Q1 2019: -$14.05 million | Q2 2019: -$13.32 million | Q3 2019: -$16.77 million | Q1 2020: -$20.29 million | Q2 2020: -$23.14 million | Q3 2020: -$16.40 million | Q1 2021: $176.56 million | Q2 2021: -$14.31 million | Q3 2021: -$11.68 million | Q1 2022: -$16.27 million | Q2 2022: -$14.30 million | Q3 2022: -$12.80 million | Q1 2023: -$14.89 million | Q2 2023: -$14.17 million | Q3 2023: -$12.03 million | Q1 2024: -$17.42 million | Q2 2024: -$20.52 million | Q3 2024: -$13.23 million | Q1 2025: -$12.55 million | Q2 2025: -$5.07 million | Q3 2025: -$12.52 million.
- Over the full 11 years of available data (2015 to 2025), Ovid Therapeutics Inc.'s Operating Income Loss has declined by 221.7%.
- Historical annual values: Fiscal year 2025: -$42.44 million | Fiscal year 2024: -$61.89 million | Fiscal year 2023: -$59.28 million | Fiscal year 2022: -$55.55 million | Fiscal year 2021: $124.21 million | Fiscal year 2020: -$81.43 million | Fiscal year 2019: -$61.41 million | Fiscal year 2018: -$52.93 million | Fiscal year 2017: -$65.01 million | Fiscal year 2016: -$22.54 million | Fiscal year 2015: -$13.19 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: